Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 15

PMID 35163328

Authors

Nura A Mohamed

Isra Marei

Sergio Crovella

Haissam Abou-Saleh

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality worldwide. However, despite the recent developments in the management of CVDs, the early and long outcomes vary considerably in patients, especially with the current challenges facing the detection and treatment of CVDs. This disparity is due to a lack of advanced diagnostic tools and targeted therapies, requiring innovative and alternative methods. Nanotechnology offers the opportunity to use nanomaterials in improving health and controlling diseases. Notably, nanotechnologies have recognized potential applicability in managing chronic diseases in the past few years, especially cancer and CVDs. Of particular interest is the use of nanoparticles as drug carriers to increase the pharmaco-efficacy and safety of conventional therapies. Different strategies have been proposed to use nanoparticles as drug carriers in CVDs; however, controversies regarding the selection of nanomaterials and nanoformulation are slowing their clinical translation. Therefore, this review focuses on nanotechnology for drug delivery and the application of nanomedicine in CVDs.

Citing Articles

Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy.

Chen Q, Yu T, Gong J, Shan H Molecules. 2025; 30(4).

PMID: 40005272 PMC: 11858567. DOI: 10.3390/molecules30040962.

Therapeutic potentials of allicin in cardiovascular disease: advances and future directions.

Gao Y, Wang B, Qin G, Liang S, Yin J, Jiang H Chin Med. 2024; 19(1):93.

PMID: 38956680 PMC: 11218272. DOI: 10.1186/s13020-024-00936-8.

Revolutionizing Cardiovascular Health with Nano Encapsulated Omega-3 Fatty Acids: A Nano-Solution Approach.

Gill R, Al-Badr M, AlGhouti M, Mohamed N, Abou-Saleh H, Rahman M Mar Drugs. 2024; 22(6).

PMID: 38921567 PMC: 11204627. DOI: 10.3390/md22060256.

Exploring Sustainable Agriculture with Nitrogen-Fixing Cyanobacteria and Nanotechnology.

Nawaz T, Gu L, Fahad S, Saud S, Bleakley B, Zhou R Molecules. 2024; 29(11).

PMID: 38893411 PMC: 11173783. DOI: 10.3390/molecules29112534.

Multivariate Analysis of Solubility Parameters for Drug-Polymer Miscibility Assessment in Preparing Raloxifene Hydrochloride Amorphous Solid Dispersions.

Moreira G, Taveira S, Martins F, Wagner K, Marreto R AAPS PharmSciTech. 2024; 25(5):127.

PMID: 38844724 DOI: 10.1208/s12249-024-02844-4.

References

Jaffer F, Libby P, Weissleder R . Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol. 2009; 29(7):1017-24. PMC: 2733228. DOI: 10.1161/ATVBAHA.108.165530. View

Lee S, Shroyer K, Markham N, Cool C, Voelkel N, Tuder R . Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998; 101(5):927-34. PMC: 508641. DOI: 10.1172/JCI1910. View

Das A, Mukherjee P, Singla S, Guturu P, Frost M, Mukhopadhyay D . Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide. Nanotechnology. 2010; 21(30):305102. PMC: 4154635. DOI: 10.1088/0957-4484/21/30/305102. View

Thompson S, Nedkoff L, Katzenellenbogen J, Hussain M, Sanfilippo F . Challenges in Managing Acute Cardiovascular Diseases and Follow Up Care in Rural Areas: A Narrative Review. Int J Environ Res Public Health. 2019; 16(24). PMC: 6950682. DOI: 10.3390/ijerph16245126. View

Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge R . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6):800-4. DOI: 10.1164/ajrccm.165.6.2106079. View

Benza R, Miller D, Barst R, Badesch D, Frost A, McGoon M . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448-456. DOI: 10.1378/chest.11-1460. View

Ilinskaya A, Dobrovolskaia M . Immunosuppressive and anti-inflammatory properties of engineered nanomaterials. Br J Pharmacol. 2014; 171(17):3988-4000. PMC: 4243973. DOI: 10.1111/bph.12722. View

Choi Y, Han H . Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig. 2018; 48(1):43-60. PMC: 6244736. DOI: 10.1007/s40005-017-0370-4. View

Badlam J, Bull T . Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. Ther Adv Chronic Dis. 2017; 8(2-3):47-64. PMC: 5354132. DOI: 10.1177/2040622317693218. View

10.

Liu Q, Jing Z . The limits of oral therapy in pulmonary arterial hypertension management. Ther Clin Risk Manag. 2015; 11:1731-41. PMC: 4664513. DOI: 10.2147/TCRM.S49026. View

11.

Katsuki S, Matoba T, Koga J, Nakano K, Egashira K . Anti-inflammatory Nanomedicine for Cardiovascular Disease. Front Cardiovasc Med. 2018; 4:87. PMC: 5743792. DOI: 10.3389/fcvm.2017.00087. View

12.

Wang L, Shi C, Wright F, Guo D, Wang X, Wang D . Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment. Cancer Res. 2017; 77(12):3293-3305. PMC: 5478165. DOI: 10.1158/0008-5472.CAN-16-3119. View

13.

Rabinovitch M . Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012; 122(12):4306-13. PMC: 3533531. DOI: 10.1172/JCI60658. View

14.

Hotze E, Phenrat T, Lowry G . Nanoparticle aggregation: challenges to understanding transport and reactivity in the environment. J Environ Qual. 2011; 39(6):1909-24. DOI: 10.2134/jeq2009.0462. View

15.

Pugliese S, Poth J, Fini M, Olschewski A, El Kasmi K, Stenmark K . The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am J Physiol Lung Cell Mol Physiol. 2014; 308(3):L229-52. PMC: 4338929. DOI: 10.1152/ajplung.00238.2014. View

16.

Agarwal H, Nakara A, Shanmugam V . Anti-inflammatory mechanism of various metal and metal oxide nanoparticles synthesized using plant extracts: A review. Biomed Pharmacother. 2018; 109:2561-2572. DOI: 10.1016/j.biopha.2018.11.116. View

17.

Patra J, Das G, Fraceto L, Campos E, Del Pilar Rodriguez-Torres M, Acosta-Torres L . Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018; 16(1):71. PMC: 6145203. DOI: 10.1186/s12951-018-0392-8. View

18.

Long L, Ormiston M, Yang X, Southwood M, Graf S, Machado R . Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med. 2015; 21(7):777-85. PMC: 4496295. DOI: 10.1038/nm.3877. View

19.

Tu L, de Man F, Girerd B, Huertas A, Chaumais M, Lecerf F . A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med. 2012; 186(7):666-76. PMC: 5106524. DOI: 10.1164/rccm.201202-0309OC. View

20.

Ross C, Ang D, Almeida-Porada G . Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis. Front Immunol. 2019; 10:266. PMC: 6409305. DOI: 10.3389/fimmu.2019.00266. View